Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN [NASD]
AstraZeneca PLC
Index- P/E38.77 EPS (ttm)1.43 Insider Own0.50% Shs Outstand2.62B Perf Week-1.24%
Market Cap172.80B Forward P/E12.60 EPS next Y4.41 Insider Trans0.00% Shs Float2.62B Perf Month-6.53%
Income3.77B PEG1.92 EPS next Q0.66 Inst Own14.80% Short Float0.24% Perf Quarter-4.81%
Sales29.53B P/S5.85 EPS this Y137.20% Inst Trans4.47% Short Ratio0.64 Perf Half Y12.90%
Book/sh5.97 P/B9.31 EPS next Y25.39% ROA5.60% Target Price68.58 Perf Year-0.68%
Cash/sh5.03 P/C11.06 EPS next 5Y20.20% ROE26.00% 52W Range46.48 - 60.93 Perf YTD11.14%
Dividend1.40 P/FCF101.41 EPS past 5Y1.70% ROI12.20% 52W High-8.81% Beta0.55
Dividend %2.52% Quick Ratio1.00 Sales past 5Y1.50% Gross Margin76.20% 52W Low19.54% ATR0.84
Employees76100 Current Ratio1.20 Sales Q/Q31.00% Oper. Margin19.20% RSI (14)34.58 Volatility1.44% 1.17%
OptionableYes Debt/Eq1.75 EPS Q/Q-27.50% Profit Margin12.80% Rel Volume0.69 Prev Close56.60
ShortableYes LT Debt/Eq1.57 EarningsJul 29 BMO Payout65.40% Avg Volume10.03M Price55.56
Recom1.60 SMA20-4.11% SMA50-4.09% SMA2002.97% Volume6,928,711 Change-1.84%
Aug-12-21Resumed JP Morgan Overweight
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Sep-18-21 11:30AM  
11:30AM  
09:05AM  
07:30AM  
Sep-17-21 04:41PM  
03:59PM  
03:56PM  
02:29PM  
02:09PM  
01:21PM  
01:11PM  
01:03PM  
12:28PM  
12:05PM  
11:17AM  
10:10AM  
07:58AM  
07:45AM  
07:30AM  
Sep-16-21 10:50AM  
10:30AM  
09:31AM  
Sep-15-21 02:40PM  
01:51PM  
10:53AM  
03:10AM  
Sep-14-21 05:09AM  
Sep-13-21 11:15PM  
04:45PM  
02:14PM  
01:40PM  
10:35AM  
05:51AM  
Sep-10-21 01:02PM  
11:25AM  
08:12AM  
Sep-09-21 03:28PM  
02:38PM  
02:24PM  
02:19PM  
11:51AM  
11:00AM  
09:39AM  
08:22AM  
08:04AM  
07:38AM  
07:33AM  
07:00AM  
06:38AM  
Sep-08-21 01:37PM  
11:20AM  
07:42AM  
Sep-07-21 04:05PM  
02:12PM  
01:03PM  
11:29AM  
10:38AM  
09:21AM  
08:41AM  
12:01AM  
Sep-06-21 12:44PM  
10:55AM  
09:56AM  
Sep-04-21 07:32AM  
Sep-03-21 01:58PM  
12:48PM  
10:57AM  
10:51AM  
09:26AM  
08:57AM  
06:34AM  
05:53AM  
Sep-02-21 02:18PM  
08:18AM  
Sep-01-21 02:14PM  
Aug-31-21 01:25PM  
10:11AM  
07:12AM  
07:00AM  
06:23AM  
Aug-30-21 04:42PM  
02:06PM  
Aug-29-21 05:20AM  
04:12AM  
Aug-27-21 02:07PM  
08:32AM  
08:09AM  
Aug-26-21 03:02PM  
02:37PM  
11:04AM  
Aug-25-21 01:38PM  
11:27AM  
06:52AM  
03:14AM  
Aug-24-21 02:16PM  
11:29AM  
Aug-23-21 01:57PM  
07:48AM  
04:18AM  
04:09AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.